Alkermes plc.

Nasdaq: ALKS · SEC EDGAR filings

Results on file1
Average 24h move+7.13%across 1 result with a complete 24h price
1 resultAlkermes plc.
Met endpoint

LUMRYZ

Phase 3 Idiopathic Hypersomnia

Alkermes plc. ALKS

24h stock move +7.13%

For information only. Not investment or medical advice. Prices are historical, from consolidated market data, and may contain errors. Always check the original source.